Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT2104 oral dosing and endotoxin challenge in healthy male volunteers
NL-OMON32755Phase 1Not yet recruiting
- Sponsor
- Sirtris Pharmaceuticals
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of SRT2104 in chronic inflammation (3 arms), sponsored by Sirtris Pharmaceuticals. Primary endpoint: Inflammatory response after endotoxin challenge. Planned start Nov 2009; status: not yet recruiting.
02
Drugs
SRT2104
03
Conditions
chronic inflammation
Beyond the preview
Go deeper on NL-OMON32755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32755.